This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 21363803
Submitted by lobbyist on: September 10, 2014 04:35:31 PM
Accepted by Registrar on: September 11, 2014 02:02:28 PM
Lobbyist Information
| Fitzgerald, Laura |
| 7811 Buena Vista Road | |
|
Edmonton, Alberta, AB, T5R 5R3
|
780-975-9773 |
| Canada |
BC Public Office Background
Lobbyist Firm Information
| Laura Fitzgerald and Associates Inc. |
| 7811 Buena Vista Road | |
|
Edmonton, Alberta, BC, T5R 5R3
|
780-975-9773 |
| Canada |
Client Information
| Lundbeck Canada Inc. |
| Lundbeck Canada Inc. is a subsidiary of H. Lundbeck A/S, an international research-based Pharmaceutical company focused on brain diseases and oncology. Based in Montreal, Lundbeck Canada Inc. has been active in the Canadian pharmaceutical industry for almost two decades, marketing products for the treatment of depression, anxiety, Alzheimer's disease, schizophrenia, bipolar disorders, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute promyelocytic leukemia. Through research, development, education, and partnerships with other companies and patient organizations, Lundbeck employees are improving the quality of life for people living with brain diseases and cancer. |
| 1000 rue de la Gauchetière Ouest Bureau 500 | |
|
Montréal, QC, H3B 4W5
|
514-844-8515 |
| Canada |
Relevant Affiliates
Type:
| Business Name | Mailing Address | Contact Information |
|---|---|---|
| H. Lundbeck A/S |
Ottiliavej 9 2500
Valby, Denmark, Denmark |
Phone: |
Government or Government Agency Funding
Other Controlling or Directing Interests
Undertaking Information
| January 1, 2014 | |
| April 1, 2015 |
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder
Awarding, amendment or termination of a contract, grant or financial benefit
1) Conduct MA pre-meeting briefs and post meeting debrief to effectively transition him into his new role and ensure success in ongoing provincial negotiations. Briefings will include: program and organizational overviews, background on meeting KOL's, update/monitor relevant political/policy landscape, research as needed. 2) Identify process steps (post pCODR decision), monitor timelines, organize meetings with decision makers/process influencers, and support MA's management of agency specific files to achieve public reimbursement of TRISENOX¿ in Western Canada. 3) Identify/map process steps (post CADTH and pCPA decision), monitor timelines, organize meetings with decision makers/process influencers, and support MA's management of agency specific files to achieve public reimbursement (Government and agency)of BRINTELLIX¿ in Western Canada.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | September 10, 2014 |